5 drug categories having the biggest impact on pharma spending in the future

Dear All,

The transformations taking place throughout all healthcare sectors will have repercussions for the pharmaceutical industry. How will they affect industry prospects, and what are the implications for drug manufacturers be affected?

According to Matthew Hudes, US Managing Principal for Deloitte’s Biopharma practice, the pharmaceutical industry is poised to enter an “inflection point” in which it may produce more medicines that have a dramatic impact on disease than ever before.

This is being spurred, Hudes said, by the industry’s need to replenish a tidal wave of patent expirations and by a new-found willingness to embrace “open innovation,” the practice of working with other organizations, even competitors, in obtaining the medical and scientific expertise needed to develop better therapies. 

Deloitte recently issued a report showing that drugs sourced via open innovation are 3 times more likely to achieve late-phase clinical success versus those cultivated under an in-house, closed-model approach.

“The new products hitting the market foreshadow a new era in which biopharma plays a more significant role in healthcare,” said Hudes. “Among other areas, will be a sizable wave of activity in infectious disease treatments, immunotherapies and the treatment of extreme clinical phenotypes caused by rare genetic variations, such as PCSK9, in cholesterol.  These are some of the conditions in which biopharma can make a substantial impact on outcomes and costs.”

With that context, here are 5 drug categories that may command the most impact on pharma spending in the near future:

1. Hepatitis C

2. Oncology

3. PCSK9 inhibitors (proprotein convertase subtilisin/kexin 9) enzyme inhibitors

4.  Cystic fibrosis

5. Heart failure

Source: http://formularyjournal.modernmedicine.com/formulary-journal/news/5-drug-categories-having-biggest-impact-pharma-spending

Comments

Popular posts from this blog

China-India joint summit discusses bilateral trade to improve pharma industry

PHYTOCON 2018 - Commercialization of medicinal plant products: Lab techniques to trade_14 April 2018